UCB gets specialized

Koroneos, George
October 2008
Pharmaceutical Representative;Oct2008, Vol. 38 Issue 10, p8
The article reports on the restructuring plan of UCB Pharma Inc. dubbed as "SHAPE." The pharmaceutical company plans to dismiss 17% of its workforce or 2,000 employees to reestablish a company that will specialize on drug development. It will allow the company to concentrate on central nervous system and immunology treatment areas and relocate $300 million for its centers of excellence. The repositioning of the company include the purchase of the British biotech Celltech in 2004.


Related Articles

  • UCB/Schwarz: a leading CNS proposition moves a step closer.  // PharmaWatch: CNS;Jan2007, Vol. 6 Issue 1, p4 

    The article focuses on the acquisition of Schwarz Pharma Inc. by UCB Pharma Inc. The acquisition gives UCB the excess of 76% of the share capital of Schwarz Pharma and is expected to create a leading neurology-focused pharmaceuticals group. From an earnings perspective, the acquisition is...

  • UCB: IV Keppra gets EU regulatory nod.  // PharmaWatch: Monthly Review;Jun2006, Vol. 5 Issue 6, p23 

    The article reports that UCB has been awarded European approval for IV Keppra anti-epileptic agents. The company's strategy for Keppra is to focus exclusively on penetrating the epilepsy market. The European Agency for the Evaluation of Medicinal Products has also recommended the drug for use in...

  • Drug repositioning strategies: a different approach to innovation.  // PharmaWatch: Monthly Review;Jul2009, Vol. 8 Issue 7, p34 

    The article focuses on drug repositioning as an innovative business approach for the pharmaceutical industry. It relates that the strategy offers advantage in reducing the cost, risk and time to market in drug development. It also notes that the strategy relies on an element of molecular...

  • Torre Lazur McCann. Arnold, Matthew // Medical Marketing & Media;Jul2008, Vol. 43 Issue 7, p143 

    The article focuses on the growth and performance of the healthcare marketing agency Torre Lazur McCann. It mentions that six new chemical entities are being launched by the agency in the forthcoming year. It states that the agency has landed assignments for Novartis AG's flu vaccines and UCB...

  • Accounts in Action.  // Pharmaceutical Executive;Dec2002, Vol. 22 Issue 12, p82 

    Reports developments related to pharmaceutical industry in the U.S. as of December 2002. Launch of the schizophrenia treatment by Corbett; Recruitment of Merkley Newman Harty to be the consumer advertising agency for Prevacid; Partnership between Elan Pharmaceuticals Inc. and UCB Pharma Inc. on...

  • New in the Marketplace.  // Drugs & Therapy Perspectives;Nov2003, Vol. 19 Issue 11, p26 

    List several pharmaceutical product launches and approvals identified in international markets as of November 2003. Humira from Abbott Laboratories; Arava from Aventis; Keppra from UCB Pharma.

  • New formulations.  // Formulary;Oct2006, Vol. 41 Issue 10, p492 

    The article examines the safety and efficacy of Keppra or levetiracetam injection, an antiepileptic drug, from UCB Pharma Inc. Epileptics who participated in a clinical trial of the drug claim that their seizures reduced after taking the antiepileptic. One downside of the drug is the occurrence...

  • UCB/Schwarz: a leading CNS proposition moves a step closer.  // PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p18 

    The article presents the author's view regarding the $5.5 billion takeover of Schwarz Pharma AG by UCB Pharma Inc. According to the author, the acquisition allowed UCB to receive tenders in excess of 76 percent of the share capital of Schwarz Pharma. Also, the deal will create a leading...

  • ImmunoMedics/UCB: looking to lupus.  // PharmaWatch: Monthly Review;Jun2006, Vol. 5 Issue 6, p30 

    The article reports on ImmunoMedics' announcement of a profitable licensing deal with European biopharmaceutical company UCB for epratuzumab, a B-cell targeted therapy for autoimmune disorders like lupus. According to the company, its shares have increased by 14% after the announcement. UCB has...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics